Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, often called magic mushrooms. The body converts it into psilocin, which acts on serotonin receptors and changes how a person experiences thoughts, emotions and the world around them. Psilocin is also naturally present in some mushrooms, so it is not produced exclusively through this conversion.<\/p>\n\n\n\n
You may have come across psilocybin in a discussion about mushrooms, a documentary about the brain or a headline about depression treatment. Each introduces a different part of the story. Understanding how those parts fit together helps explain both the interest in this compound and the questions scientists are still trying to answer.<\/p>\n\n\n\n
What does psilocybin actually do? Why might it help some people while causing distress in others? And what separates a psychedelic experience from the treatment studied in a clinical trial?<\/p>\n\n\n\n
Psilocybin occurs naturally<\/a> in several groups of fungi, particularly the genus Psilocybe<\/em>. These mushrooms grow in different regions and climates. A 2022 review by Van Court and colleagues, published in Fungal Biology<\/em>, describes hundreds of psilocybin-containing species<\/a> across at least seven genera. This reflects a diverse group of fungi whose classification and chemical composition remain subjects of research.<\/p>\n\n\n\n Names you may encounter include Psilocybe cubensis<\/em>, Psilocybe semilanceata<\/em> and Psilocybe cyanescens<\/em>. The liberty cap, P. semilanceata<\/em>, occurs in temperate grasslands in Europe and other parts of the world. Some species belonging to another genus, Panaeolus<\/em>, also contain psilocybin.<\/p>\n\n\n\n A species name, however, does not tell you exactly how much psilocybin a mushroom contains. Chemical composition varies, which is one reason whole mushrooms cannot be treated as equivalent to a standardised pharmaceutical preparation. Identification creates a separate concern: poisonous species can resemble psilocybin-containing mushrooms.<\/p>\n\n\n\n Psilocybin is a precursor that the body converts into psilocin, the compound primarily responsible for its psychedelic effects.<\/strong> The names are similar enough to cause confusion, but the distinction makes the science easier to follow.<\/p>\n\n\n\n Scientists describe psilocybin as a prodrug<\/em>: a substance converted by the body into a more pharmacologically active form. Enzymes remove a phosphate group from the psilocybin molecule, producing psilocin. Psilocin can cross the blood\u2013brain barrier, which regulates the movement of substances from the bloodstream into brain tissue, and interact with serotonin receptors.<\/p>\n\n\n\n Both compounds can occur in mushrooms. When a clinical study administers psilocybin, however, its psychedelic effects are largely mediated by the psilocin formed afterwards. One name describes what researchers give participants, while the other helps explain what happens next inside the body.<\/p>\n\n\n\n After conversion from psilocybin, psilocin acts as a partial agonist at serotonin 5-HT2A receptors<\/strong>. In everyday language, this means it binds to these receptors and activates them, although not in the same way or to the same maximum extent as a full agonist in a given experimental system. Serotonin is a chemical messenger involved in functions such as mood and perception.<\/p>\n\n\n\n This receptor activity is the starting point, rather than the whole explanation. Brain-imaging research shows changes in how activity is coordinated across networks of brain regions. These findings help scientists investigate why perception, emotion and the sense of self can all feel different during a psychedelic experience.<\/p>\n\n\n\n Although discussions often focus on consciousness, psilocybin also has measurable physical effects. Blood pressure and heart rate can rise, and some people experience nausea, headaches or dizziness. Clinical research therefore includes medical assessment and monitoring, even when the condition being studied is psychological.<\/p>\n\n\n\n A 2024 systematic review and meta-analysis combined six randomised trials involving 528 participants. Headache, nausea, anxiety, dizziness and elevated blood pressure were more likely after therapeutic doses of psilocybin than after the comparison treatments. The acute adverse effects examined generally resolved within 48 hours. These findings describe monitored trials, so they do not guarantee that every reaction outside a clinical setting will be mild or short-lived.<\/p>\n\n\n\n Psilocybin can change how a person perceives colours, sounds, time and their own thoughts. Emotions may become more intense, familiar surroundings may seem unfamiliar, and the usual sense of being separate from the environment can become less distinct. Some people describe connection or insight; others experience confusion, fear or loss of control.<\/p>\n\n\n\n Researchers discuss these effects partly in terms of set and setting<\/em>. \u201cSet\u201d refers to the person\u2019s mental state and expectations. \u201cSetting\u201d includes the physical and social environment, but in clinical research it also encompasses trained staff, the treatment room, structured procedures and monitoring. It is part of the intervention being studied, rather than simply a comfortable place to spend several hours.<\/p>\n\n\n\n A small study published by Siegel and colleagues in Nature<\/em> in 2024 offers one view of what happens in the brain. The study enrolled seven healthy adults and found that psilocybin disrupted the usual synchronisation of brain activity, with pronounced changes in the default mode network<\/strong>, which contributes to internally focused thinking, including thoughts about oneself. The findings describe desynchronisation and changes in functional connectivity, meaning patterns of coordinated activity between brain regions. They do not demonstrate a literal \u201cbrain reset\u201d or establish recovery from depression.<\/p>\n\n\n\n Researchers are investigating psilocybin for depression, psychological distress associated with serious illness and some substance use disorders. Participants usually receive a measured preparation alongside psychological support. The intervention includes assessment, supervision and follow-up, as well as the compound itself.<\/p>\n\n\n\n This context matters when reading a headline about \u201cmagic mushrooms treating depression\u201d. The underlying study may involve a pharmaceutical preparation, carefully selected patients and several appointments with a clinical team.<\/p>\n\n\n\n Clinical trials suggest that<\/strong> psilocybin with psychological support<\/a> can reduce depressive symptoms in some patients. They do not establish that it reliably or permanently cures depression.<\/p>\n\n\n\n In a 2023 trial by Raison and colleagues, published in JAMA<\/em>, 104 adults with major depressive disorder received either 25 mg of psilocybin or 100 mg of niacin<\/strong>, with psychological support in both groups. Niacin served as an active placebo because it can cause noticeable effects, including skin flushing. This was intended to make treatment allocation harder to guess, although niacin does not reproduce the psychedelic experience. The psilocybin group showed greater improvement in depressive symptoms over six weeks.<\/p>\n\n\n\n A 2022 trial by Goodwin and colleagues, published in the New England Journal of Medicine<\/em>, involved 233 adults with treatment-resistant depression. Participants received 25 mg, 10 mg or 1 mg of psilocybin<\/strong>, alongside psychological support. The primary outcome, meaning the main measure used to evaluate treatment, was the change in depression severity at three weeks. The 25 mg group improved significantly more than the 1 mg control group; the 10 mg group did not.<\/p>\n\n\n\n Sustained response through 12 weeks was a secondary outcome, and the trial did not establish a statistically clear advantage for 25 mg over 1 mg on that measure. This does not mean nobody experienced lasting improvement. It means that the evidence for a longer-lasting group difference was less conclusive than the three-week result. Suicidal thoughts or behaviour, or self-injury, occurred across dose groups, reinforcing the need for ongoing assessment without establishing that psilocybin caused every event.<\/p>\n\n\n\n For anxiety, an important part of the evidence comes from people living with life-threatening cancer. A small randomised trial reported reductions in anxiety and depression associated with that illness. These findings should not be generalised to every anxiety condition: cancer-related distress, generalised anxiety disorder and panic disorder are different clinical problems.<\/p>\n\n\n\n Alcohol use disorder is another area with evidence from a randomised clinical trial. In a 2022 study by Bogenschutz and colleagues, participants received psychotherapy alongside either psilocybin or an active placebo. During the 32-week comparison period, heavy drinking days accounted for 9.7% of days in the psilocybin group and 23.6% in the comparison group<\/strong>.<\/p>\n\n\n\n Those figures describe reduced heavy drinking within a structured treatment programme. They do not mean that everyone stopped drinking or that taking psilocybin independently would produce the same outcome. Psychotherapy and clinical support were part of what researchers tested.<\/p>\n\n\n\n Other possible applications, including chronic pain, are being investigated. These remain research questions rather than established benefits. Each condition needs evidence showing who may benefit, how much improvement occurs and what risks accompany treatment.<\/p>\n\n\n\n Psilocybin-assisted therapy<\/a> usually involves a series of appointments rather than a single drug-administration session. Protocols differ, but most include assessment, preparation, supervised administration and follow-up.<\/p>\n\n\n\n The process generally follows four stages:<\/p>\n\n\n\n The word integration<\/em> can sound abstract. In practice, it refers to discussing what happened and exploring what, if anything, it means for ongoing treatment and daily life. An intense experience is not automatically a useful one, and feeling better immediately afterwards does not establish a lasting improvement. Researchers are still examining how different forms and amounts of psychological support contribute to outcomes.<\/p>\n\n\n\n The results justify continued investigation, but psychedelic studies present some unusual challenges. Participants can often guess whether they received the active drug. This makes blinding<\/em>, keeping treatment allocation unknown, difficult and leaves room for expectations to influence outcomes.<\/p>\n\n\n\n Safety findings also need context. A 2024 systematic review and meta-analysis by Hinkle and colleagues in JAMA Psychiatry<\/em> examined classic psychedelic research, rather than psilocybin alone. Serious adverse events were uncommon overall but did occur, particularly in participants with existing neuropsychiatric conditions. The authors also identified concerns about incomplete reporting and missed adverse events.<\/p>\n\n\n\n An adverse event is something undesirable that happens during a study; it is not automatically a proven reaction to the drug. Equally, incomplete reporting makes it harder to estimate risk confidently. Positive results therefore need to be read alongside participant selection, monitoring procedures and the length of follow-up.<\/p>\n\n\n\n Psilocybin does not typically produce physical dependence or a characteristic physical withdrawal syndrome. Repeated use can produce rapid tolerance, meaning that the same amount has a weaker effect. Tolerance describes a change in the body\u2019s response; addiction concerns patterns of use and their consequences.<\/p>\n\n\n\n That distinction matters because a substance can cause problems without producing physical withdrawal. If use begins to interfere with relationships, work or mental health, those consequences deserve attention regardless of its dependence potential.<\/p>\n\n\n\n The side effects of psilocybin range from physical discomfort to psychological distress. Some reactions occur during the main experience, while others may continue afterwards.<\/p>\n\n\n\n Commonly reported acute adverse effects include:<\/p>\n\n\n\n More concerning reactions include panic, paranoia, psychotic symptoms and recurring visual disturbances. Calling an experience a \u201cbad trip\u201d can make it sound less serious than it feels to the person going through it. Symptoms that persist after the main effects have ended warrant medical assessment.<\/p>\n\n\n\n Medical and psychiatric history also affect risk. Clinical teams review these factors alongside medication use because interactions can alter effects or create additional concerns. Prescribed treatment should not be stopped independently in preparation for taking psilocybin.<\/p>\n\n\n\n Taking too much psilocybin can cause severe adverse effects, even though life-threatening toxicity is uncommon.<\/strong> Excessive exposure may lead to intense panic, agitation, confusion or vomiting. A low tendency to cause physical dependence does not prevent an acute medical emergency.<\/p>\n\n\n\n Serious neurological complications have been documented in individual case reports. For example, a 2023 report described increased seizure activity after psychedelic mushroom ingestion in a person with pre-existing, treatment-resistant epilepsy. This illustrates a possible risk in a vulnerable individual; it does not establish seizures as a typical effect or tell us how frequently they occur in the wider population.<\/p>\n\n\n\n A separate danger is consuming a poisonous mushroom mistaken for a psilocybin-containing species. Suspected poisoning should not be dismissed as an unusually strong psychedelic experience. Contact a poison centre promptly if poisonous mushroom ingestion is possible, and seek emergency medical help for collapse, breathing difficulties or seizures.<\/p>\n\n\n\n Several practical questions come up repeatedly when people first read about psilocybin. These answers help put the research into everyday terms.<\/p>\n\n\n\n The main psychedelic effects commonly last around four to six hours, although duration varies. Some people feel tired or emotionally unsettled afterwards, so the end of the main experience does not always mean an immediate return to normal functioning.<\/p>\n<\/details>\n\n\n\n As of the available 2026 regulatory information, psilocybin has no FDA-approved therapeutic indication. The FDA has granted Breakthrough Therapy designation to specific psilocybin development programmes<\/strong>, helping accelerate development and regulatory review. In 2026, it also issued national priority vouchers to companies investigating psilocybin for depression. Neither mechanism constitutes marketing approval or an FDA determination that a treatment is safe and effective.<\/p>\n\n\n\n Legal availability depends on jurisdiction<\/a>. Some countries permit restricted medical access under specific arrangements, while psilocybin remains controlled in many places, including Poland, where psilocybin and psilocin are listed as controlled psychotropic substances<\/a>. Research findings do not change those legal restrictions by themselves.<\/p>\n<\/details>\n\n\n\n A pleasant experience is not a reliable measure of treatment success. Clinical studies report anxiety and other difficult reactions during sessions, while outcomes are assessed through changes in symptoms over time. How a session feels and whether someone\u2019s condition improves are related questions, but they are not interchangeable.<\/p>\n<\/details>\n\n\n\n No. Whole mushrooms contain variable mixtures of compounds, while clinical trials commonly use a preparation containing a defined amount of psilocybin. Trials also include screening, support and monitoring. Their results cannot establish the safety or effectiveness of an unstandardised mushroom product.<\/p>\n<\/details>\n\n\n\n Piotr Kwiatkowski<\/strong> is the founder of MYKOLAB and a self-taught mycology enthusiast who has been developing his knowledge through hands-on practice and personal experiments since 2020. In February 2022, he turned his interest in fungi into a professional business by founding a company that produces mushroom grow kits.<\/p>\n\n\n\n Today, he runs a 550 m\u00b2 production facility, and his company has produced tens of thousands of mushroom grow kits for individual customers and international business partners. His work focuses on developing proprietary technologies, maintaining production quality and consistency, and making mushroom cultivation simpler.<\/p>\n\n","protected":false},"excerpt":{"rendered":" Psilocybin is a naturally occurring psychedelic compound found in certain mushrooms, often called magic mushrooms. The body converts it into psilocin, which acts on serotonin receptors and changes how a person experiences thoughts, emotions and the world around them. Psilocin is also naturally present in some mushrooms, so it is not produced exclusively through this […]<\/p>\n","protected":false},"author":4,"featured_media":8101,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[37,72],"tags":[],"class_list":["post-8107","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","category-psilocybin-medicine"],"yoast_head":"\nWhat is the difference between psilocybin and psilocin?<\/h2>\n\n\n\n
How does psilocybin work?<\/h2>\n\n\n\n
How does psilocybin affect the human body?<\/h3>\n\n\n\n
How does psilocybin affect the human mind?<\/h3>\n\n\n\n
What are the medical and therapeutic uses of psilocybin?<\/h2>\n\n\n\n
Does psilocybin treat depression and anxiety?<\/h3>\n\n\n\n
What other conditions might psilocybin help with?<\/h3>\n\n\n\n
What does psilocybin-assisted therapy look like?<\/h2>\n\n\n\n
\n
How much can we conclude from the research?<\/h2>\n\n\n\n
Is psilocybin addictive?<\/h2>\n\n\n\n
What are the side effects of psilocybin?<\/h2>\n\n\n\n
\n
Can you overdose on psilocybin?<\/h2>\n\n\n\n
Frequently asked questions about psilocybin<\/h2>\n\n\n\n
How long do psilocybin effects last?<\/h3><\/summary>\n\n\n
Is psilocybin an approved medicine?<\/h3><\/summary>\n\n\n
Does psilocybin therapy have to feel pleasant to be effective?<\/h3><\/summary>\n\n\n
Are magic mushrooms equivalent to clinical psilocybin?<\/h3><\/summary>\n\n\n
Article author<\/h2>\n\n\n\n